Cancer Vaccines
Vical Expands Applications of Vaxfectin(R) Adjuvant for Infectious Disease and Cancer Vaccines; 80% to 100% of High-Dose Responders in H5N1 Clinical Trials Still Responding at 6 Months
Published in Clinical Oncology Week, October 20th, 2008
Vical Incorporated (NASDAQ:VICL) today is presenting expanded clinical data and new nonclinical data demonstrating that the company's Vaxfectin(R) adjuvant may be broadly applicable in DNA- and protein-based infectious disease vaccines and peptide-based cancer vaccines. Alain P. Rolland, Pharm.D., Ph.D., Vical's Senior Vice President of Product Development, will present the data today, Wednesday, October 8, at the World Vaccine Congress (Lyon, France - October 6-9).
Vaxfectin(R)-formulated Cancer Vaccines
In a mouse study, a Vaxfectin(R)-formulated vaccine containing a peptide from Tyrosinase-Related Protein 2 (TRP-2), an antigen commonly expressed...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Oncology Week
More Articles from Clinical Oncology Week
- American Association for Cancer Research
H. Pylori bacteria may help prevent some esophageal cancers - American Cancer Society
News from Cancer: Disparities in head and neck cancer patients - American College of Medical Genetics
Study looks at psychological impact of gene test for breast cancer - Children's National Medical Center
Children's National researchers develop novel anti-tumor vaccine - Dana-Farber Cancer Institute
Study highlights benefits of end-of-life conversations for patients, caregivers - Journal of the National Cancer Institute
Older renal cancer patients appear to benefit from sorafenib treatment - More from this issue of Clinical Oncology Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
